ArticleOncotarget2017
Experience with precision genomics and tumor board, indicates frequent target identification, but barriers to delivery.
Article in Oncotarget, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 44 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
44 citing papers in PubMed, 2 syntheses or guidelines pooled it.
- Implementation of precision medicine in treating non-communicable diseases: a systematic review.Journal of translational medicine · 2025Pooled it
- Clinical Outcomes of Molecular Tumor Boards: A Systematic Review.JCO precision oncology · 2021Pooled it
- Making sense of commercial genomic reports in oncology: a structured approach from clinical practice.Frontiers in oncology · 2026Article
- Molecular reflex testing in patients with early metastatic castration-resistant prostate cancer within the PROMPT-study.British journal of cancer · 2026Observational
- Article
- The impact of targeted therapies on molecular alterations identified by an institutional molecular tumor board: an approach based on ESCAT classification.ESMO real world data and digital oncology · 2024Article
- Precision Oncology in Older Cancer Patients: A Single-Center Experience.International journal of molecular sciences · 2024Article
- NGS-Guided Precision Oncology in Breast Cancer and Gynecological Tumors-A Retrospective Molecular Tumor Board Analysis.Cancers · 2024Article
- Cancer treatment comes to age: from one-size-fits-all to next-generation sequencing (NGS) technologies.BioImpacts : BI · 2024Review
- The Molecular Tumor Board of the Regina Elena National Cancer Institute: from accrual to treatment in real-world.Journal of translational medicine · 2023Article
- Human resources for administrative work to carry out a comprehensive genomic profiling test in Japan.Cancer science · 2023Article
- Bridging therapeutic opportunities: a survey by the Italian molecular tumor board workgroup of Alliance Against Cancer.Journal of experimental & clinical cancer research : CR · 2022Article
- Impact of molecular tumour board discussion on targeted therapy allocation in advanced prostate cancer.British journal of cancer · 2022Article
- Searching of Clinical Trials Made Easier in cBioPortal Using Patients' Genetic and Clinical Profiles.Applied clinical informatics · 2022Article
- Implementing a Functional Precision Medicine Tumor Board for Acute Myeloid Leukemia.Cancer discovery · 2022Article
- Simulation studies, 3D QSAR and molecular docking on a point mutation of protein kinase B with flavonoids targeting ovarian Cancer.BMC pharmacology & toxicology · 2021Article
- Next-Generation Sequencing-Directed Therapy in Patients with Metastatic Breast Cancer in Routine Clinical Practice.Cancers · 2021Article
- Article
- Multicenter Comparison of Molecular Tumor Boards in The Netherlands: Definition, Composition, Methods, and Targeted Therapy Recommendations.The oncologist · 2021Article
- A showcase study on personalized in silico drug response prediction based on the genetic landscape of muscle invasive bladder cancer.Scientific reports · 2021Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
25 authors.
Funding
Abstract
backgroundThe ability to analyze the genomics of malignancies has opened up new possibilities for off-label targeted therapy in cancers that are refractory to standard therapy. At Mayo Clinic these efforts are organized through the Center for Individualized Medicine (CIM).
resultsPrior to GTB, datasets were analyzed and integrated by a team of bioinformaticians and cancer biologists. Therapeutically actionable mutations were identified in 65% (92/141) of the patients tested with 32% (29/92) receiving genomically targeted therapy with FDA approved drugs or in an independent clinical trial with 45% (13/29) responding. Standard of care (SOC) options were continued by 15% (14/92) of patients tested before exhausting SOC options, with 71% (10/14) responding to treatment. Over 35% (34/92) of patients with actionable targets were not treated with 65% (22/34) choosing comfort measures or passing away. MATERIALS AND
methodsPatients (N = 165) were referred to the CIM Clinic between October 2012 and December 2015. All patients received clinical genomic panel testing with selected subsets receiving array comparative genomic hybridization and clinical whole exome sequencing to complement and validate panel findings. A genomic tumor board (GTB) reviewed results and, when possible, developed treatment recommendations.
conclusionsTreatment decisions driven by tumor genomic analysis can lead to significant clinical benefit in a minority of patients. The success of genomically driven therapy depends both on access to drugs and robustness of bioinformatics analysis. While novel clinical trial designs are increasing the utility of genomic testing, robust data sharing of outcomes is needed to optimize clinical benefit for all patients.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.